XDC THE BIOCONJUGATION LEADER
LIVE

Serial Number

98069926

Owner

WuXi XDC Cayman Inc.

Attorney

Eric Lamb

First Use Date

Oct 20, 2023

Filing Date

Jul 3, 2023

Add to watchlist:

No watchlists yet
View on USPTO

XDC THE BIOCONJUGATION LEADER Trademark

Serial Number: 98069926 • Registration: 7525176

XDC THE BIOCONJUGATION LEADER is a trademark filed by WuXi XDC Cayman Inc. on July 3, 2023. The trademark is classified under Class 40 (Treatment & Processing), Class 42 (Computer & Scientific). The application is currently registered and active.

Owner Contact Info

WuXi XDC Cayman Inc. (15 trademarks)

No.11, Xinhui Ring Road
Wuxi, Jiangsu Province 214028 , CN

Entity Type: 03

Trademark Details

Filing Date

July 3, 2023

Registration Date

October 1, 2024

First Use Anywhere

October 20, 2023

First Use in Commerce

October 20, 2023

Published for Opposition

December 12, 2023

Goods & Services

Custom assembling of materials for others; custom manufacturing of pharmaceuticals; custom manufacturing of drug conjugates; custom production of pharmaceuticals; custom production of biological preparations; custom manufacturing of antibody-drug conjugates; custom manufacturing of chemical reagents; custom manufacturing of pharmaceutical preparations; custom manufacturing of biomedical preparations; custom manufacture of drug conjugates; processing of pharmaceutical preparations; processing or treating of chemical reagents; processing of antibody drugs; custom manufacturing of antibody drugs; processing of biomedical preparations; processing of biotechnology drug

Development of products for others in the field of pharmaceuticals; pharmaceutical drug development services; research and development of new products in the field of pharmaceuticals; biochemical research and development; custom design and development of chemical reagent antibodies and conjugate antibodies; research and development in the pharmaceutical, biomedicine and biotechnology fields; research and development of antibodies; research and development of conjugated antibodies; biomedical research services; development of pharmaceutical preparations and medicines; research and development of antibody-drug conjugates; research and development of drug conjugates; preclinical research and evaluation of new drugs; consulting services in the field of technology development; research and development of new products for others; scientific research and development

Filing History

NOTICE OF REGISTRATION CONFIRMATION EMAILED
Oct 1, 2024 NRCC
REGISTERED-PRINCIPAL REGISTER
Oct 1, 2024 R.PR
NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED
Aug 28, 2024 SUNA
ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED
Aug 28, 2024 CNPR
STATEMENT OF USE PROCESSING COMPLETE
Jul 7, 2024 SUPC
CASE ASSIGNED TO INTENT TO USE PARALEGAL
Jul 6, 2024 AITU
USE AMENDMENT FILED
May 29, 2024 IUAF
TEAS STATEMENT OF USE RECEIVED
May 29, 2024 EISU
NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Feb 6, 2024 NOAM
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Dec 12, 2023 NPUB
PUBLISHED FOR OPPOSITION
Dec 12, 2023 PUBO
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Nov 22, 2023 NONP
APPROVED FOR PUB - PRINCIPAL REGISTER
Nov 3, 2023 CNSA
EXAMINER'S AMENDMENT ENTERED
Nov 3, 2023 XAEC
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
Nov 3, 2023 GNEN
EXAMINERS AMENDMENT E-MAILED
Nov 3, 2023 GNEA
EXAMINERS AMENDMENT -WRITTEN
Nov 3, 2023 CNEA
ASSIGNED TO EXAMINER
Oct 31, 2023 DOCK
NOTICE OF DESIGN SEARCH CODE E-MAILED
Aug 4, 2023 MDSC
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Aug 3, 2023 NWOS
NEW APPLICATION ENTERED
Jul 6, 2023 NWAP